imatinib

Org: South Australian Health and Medical Research Institute, Universitätsklinikum Jena, Akita University Hospital, The University of Texas MD Anderson Cancer Center, University of Chicago,

Abstract

StrateGIST 1: A first-in-human (FIH), phase 1 study of IDRX-42 in patients with metastatic gastrointestinal stromal tumors resistant to prior treatment with tyrosine kinase inhibitors (TKIs).

Org: University Hospitals Leuven, Department of General Medical Oncology, Leuven Cancer Institute, Leuven, Belgium, Oregon Health & Science University, Portland, OR, University of Miami – Sylvester Comprehensive Cancer Center, Miami, FL, Medical Oncology Department, Hospital Universitario Vall d'Hebron, Vall d'Hebron Institute of Oncology, Barcelona, Spain, Universitaetsklinikum Essen - Westdeutsches Tumorzentrum (WTZ) (West German Cancer Center), Essen, Germany,

Abstract

Disparities in frontline treatment and overall survival in the era of targeted tyrosine kinase inhibitor therapy for chronic myeloid leukemia: 2004-2021.

Org: University of Utah, Huntsman Cancer Institute,

Abstract

Peak study: A phase 3, randomized, open-label multi-center clinical study of bezuclastinib (CGT9486) and sunitinib combination versus sunitinib in patients with gastrointestinal stromal tumors (GIST).

Org: Centro de Oncologia de Precision,

Abstract

A phase 2 clinical trial of regorafenib in patients with advanced pretreated melanoma (RegoMel).

Org: Universitair Ziekenhuis Brussel, Vrije Universiteit Brussel,

Abstract

Peak part 1 summary: A phase 3, randomized, open-label multicenter clinical study of bezuclastinib (CGT9486) and sunitinib combination versus sunitinib in patients with gastrointestinal stromal tumors (GIST).

Org: Dana-Farber Cancer Institute, Harvard Medical School, Sylvester Comprehensive Cancer Center, Miami, FL, University of Miami Miller School of Medicine, Miami, FL, Mayo Clinic Florida,

Abstract

A multicohort platform trial to improve drug access for pediatric cancer patients in Japan: The PARTNER trial (NCCH2220).

Org: Department of Pediatric Oncology,

Abstract

In-depth analysis of responders in the phase 3 PhALLCON trial of ponatinib vs imatinib in newly diagnosed Ph+ ALL.

Org: Hospital Universitario Dr. José Eleuterio González, University of Milano-Bicocca, ICO – Hospital Germans Trias i Pujol, Josep Carreras Leukaemia Research Institute,

Abstract

DCC-3116 in combination with ripretinib for patients with advanced gastrointestinal stromal tumor: A phase 1/2 study.

Org: The Cancer & Hematology Centers,

Abstract

Creating a national model to build anti-cancer stewardship and quality improvement initiatives.

Org: Pharmacy Benefits Management, Dept of Veterans Affairs, Pharmacy Benefits Management Services, VA Great Lakes Health Care System - VISN 12, VISN 8 Pharmacy Benefits Management,

Abstract

Phase 1 study of NB003, a broad-spectrum KIT/PDGFRα inhibitor, in patients with advanced gastrointestinal stromal tumors (GIST).

Org: Laboratory of Carcinogenesis and Translational Research of the Ministry of Education, Beijing Cancer Hospital & Institute, Ningbo Newbay Technology Development Co., Ltd.,

Abstract

Relationship of body mass index and plasma imatinib levels in CML patients and mitigation of clinical impact using PK-guided dosing strategy.

Org: PRISM Biogénopôle APHM, Hematology, APHM,

Abstract

Correlation between imatinib trough concentration and efficacy in patients with advanced GIST with different genotypes.

Org: The First Affiliated Hospital of USTC, Anhui Provincial Hospital, Hefei, China, Sun Yat-sen University Cancer Center Gansu Hospital, Center of Gastrointestinal Surgery, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China,

Clinical trial

A Phase II Study of Imatinib Dose Escalation to 800 mg/Day in Korean Patients With Metastatic or Unresectable GIST Harboring KIT Exon 9 Mutation: Imatinib Dose Escalation

Status: Active (not recruiting), Estimated PCD: 2024-12-31

Clinical trial

Phase-III Randomized Study to Optimize TKIs Multiple Approaches - (OPTkIMA) - and Quality of Life (QoL) in Elderly Patients (≥60 Years) With Ph+ Chronic Myeloid Leukemia (CML) and MR3.0 / MR4.0 Stable Molecular Response

Status: Recruiting, Estimated PCD: 2023-12-31

Clinical trial

A Randomised Phase II Trial of Imatinib Alternating With Regorafenib Compared to Imatinib Alone for the First Line Treatment of Advanced Gastrointestinal Stromal Tumour (GIST)

Status: Active (not recruiting), Estimated PCD: 2023-12-31

Clinical trial

Open-label Multicenter Trial of Glivec® (Imatinib Mesylate, Formerly Known as STI571) in Combination With Chemotherapy (MTC) in Patients With Refractory or Relapsed Acute Myeloid Leukemia (AML)

Status: Completed, Estimated PCD: 2010-12-01

Abstract

Prior authorizations for oral anticancer drugs and delayed prescription fills.

Org: Boston, MA, Harvard Medical School,

Abstract

Mortality rate and social disparity trends with tyrosine kinase inhibitory availability in chronic myelogenous leukemia: An analysis in the US from 1999 to 2020.

Org: Hackensack University Medical Center, John Theurer Cancer Center at Hackensack Meridian Health, HMH School of Medicine, Hackensack, NJ,

Abstract

Overall survival and long-term safety in patients with advanced gastrointestinal stromal tumor previously treated with imatinib: Updated analyses from INTRIGUE.

Org: Sarcoma Unit, The Royal Marsden NHS Foundation Trust and Institute of Cancer Research, London, United Kingdom, Centre Léon Bérard, Lyon, France, Dana-Farber Cancer Institute, Boston, MA, USA, Leiden University Medical Center, Leiden, Netherlands, University Hospitals Leuven, Department of General Medical Oncology, Leuven Cancer Institute, KU Leuven, Leuven, Belgium,

Abstract

Longitudinal, prospective cardiovascular and metabolic risk in treatment-naive patients with chronic myeloid leukemia in chronic phase (CML-CP) starting tyrosine kinase inhibitor (TKI) therapy in a real-world setting.

Org: University of California San Francisco, Fred Hutchinson Cancer Center/Division of Hematology and Oncology, Roswell Park Comprehensive Cancer Center, Hackensack University Medical Center, Portland VA Health Care System and OHSU Knight Cancer Institute,

Abstract

Report of a chronic myeloid leukemia registry in a low-and middle-income setting.

Org: Nairobi Hospital Cancer Centre, University of Nairobi, Aga Khan University Hospital, Field Epidemiology and Laboratory Training Programme, Kenyatta University Teaching,

Abstract

Longitudinal follow-up and outcomes of pediatric and adult patients with SDH-deficient GIST.

Org: Pediatric Oncology Branch, Clinical Center National Institutes of Health, Center for Cancer Research, National Cancer Institute, Surgical Oncology Program, Developmental Therapeutics Branch, National Cancer Institute, Vilnius, Lithuania,

Abstract

Fluorine-18 fluorodeoxyglucose (18FDG)-uptake assessment of PDGFRA mutant gastrointestinal stromal tumors (GIST): A retrospective multicenter Italian study.

Org: Oncology Unit S. Chiara Hospital, Trento, Italy, Department of Medical and Surgical Sciences (DIMEC), University of Bologna, Bologna, Italy, Adult Mesenchymal Tumour & Rare Cancer Medical Oncology Unit, Istituto Nazionale Tumori, Milan, Italy, Adult Mesenchymal Tumour & Rare Cancer Medical Oncology Unit, Istituto Nazionale Tumori, Italy, Milan, Italy, Medical Oncology and Hematology Unit, Humanitas Cancer Center, Humanitas Clinical and Research Center-IRCCS, Rozzano, Milan, Italy,

Abstract

Safety, pharmacokinetics (PK), and clinical activity of bezuclastinib + sunitinib in previously-treated gastrointestinal stromal tumor (GIST): Results from part 1 of the phase 3 Peak study.

Org: Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College University, Dana-Farber Cancer Institute, Harvard Medical School, University Hospital Essen,

Abstract

Outcomes in patients with advanced gastrointestinal stromal tumor who did not have baseline ctDNA detected in the INTRIGUE study.

Org: Sylvester Comprehensive Cancer Center, University of Miami Health System, Miami, FL, Sarcoma Unit, The Royal Marsden NHS Foundation Trust and Institute of Cancer Research, London, United Kingdom, Dana-Farber Cancer Institute, Boston, MA, USA, Leiden University Medical Center, Leiden, Netherlands, University Hospitals Leuven, Department of General Medical Oncology, Leuven Cancer Institute, KU Leuven, Leuven, Belgium,

Abstract

Clinical utility of liquid-based comprehensive genomic profiling (CGP) in gastrointestinal stromal tumors (GIST).

Org: Boston Medical Center, Foundation Medicine, Inc., Cambridge, MA, Boston University Medical Campus, OHSU Knight Cancer Institute, Portland, OR,

Abstract

INSIGHT: A phase 3, randomized, multicenter, open-label study of ripretinib vs sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib harboring KIT exon 11 + 17 and/or 18 mutations.

Org: Dana-Farber Cancer Institute, Centre Léon Bérard, Memorial Sloan Kettering Cancer Center, Sarcoma Unit, Vall d’Hebron Institute of Oncology (VHIO),

Abstract

Identification of novel actionable SNVs using targeted comprehensive genome profiling in patients with sarcoma.

Org: OneCell Dx, Pune, Indiana University – Purdue University Indianapolis, Indx Technology, Cupertino, CA,

Abstract

Predicting the immunotherapy response based on molecular subtypes of pan-immune signatures in gastrointestinal stromal tumor.

Org: ChosenMed Technology (Zhejiang) Co., Ltd., Beijing InnoCare Pharma Tech, China National Biotec Group,

Abstract

Sex differences in localized gastrointestinal stromal tumor.

Org: Oslo University Hospital, Oslo, Norway,

Abstract

Initial results from the phase (ph) 1 portion of a ph 1/2 study of THE-630 in patients (pts) with advanced gastrointestinal stromal tumor (GIST).

Org: Dana-Farber Cancer Institute, Memorial Sloan Kettering Cancer Center, Fox Chase Cancer Center, HonorHealth Research Institute, University of Miami Sylvester Comprehensive Cancer Center,

Abstract

Treatment failure with first line imatinib for patients with chronic myeloid leukaemia in Kenya vs high-income countries.

Org: Kenyatta University Teaching, University of Nairobi, Kenyatta National Hospital, Aga Khan University Hospital,

Abstract

Efficacy and safety of ponatinib in management of chronic myeloid leukaemia: Experience from Kenya.

Org: Nairobi Hospital Cancer Centre, Kenyatta University Teaching, University of Nairobi, Kenyatta National Hospital, Field Epidemiology and Laboratory Training Programme,

Abstract

Comparing GIST outcomes between geriatric and non-geriatric patients: A population-based analysis.

Org: Worcester Academy, Northwell Health, New Hyde Park, NY, Northwell Heath,

Abstract

National overview of gastrointestinal stromal tumors: Experience from middle income setting.

Org: Hematology center after Prof. R.H. Yeolyan, Yerevan, Armenia, Hematology center after prof. Yeolyan, Yerevan, Armenia, Hematology Center after R.Yeolyan, Yerevan, Armenia, Yerevan State Medical University, Yerevan, Armenia, Hystogen Laboratory, Yerevan, Armenia,